Key Takeaways
- Genetic Drivers: Genes such as APOL1, PKD1, and PKD2 are primary influencers of Chronic Kidney Disease (CKD) risk and progression.
- Precision Medicine: Genetic insights allow for faster diagnosis and personalized treatment plans, moving away from a "one-size-fits-all" approach.
- Risk Stratification: Testing helps identify patients at risk for aggressive disease forms, enabling proactive interventions to delay end-stage kidney disease.
- Improved Outcomes: Genetic data informs better medication choices (like tolvaptan for PKD) and improves kidney transplant matching.
How genetic variants influence CKD risk and progression
CKD is a complex disease with both monogenic (single-gene) and polygenic (multiple genes) forms.
Monogenic kidney diseases follow clearer inheritance patterns and can often be confirmed through targeted genetic testing; examples include polycystic kidney disease (PKD), Alport syndrome, thin basement membrane disease, and Fabry disease.
Polygenic forms of CKD, influenced by a combination of genetic and environmental factors, present a more complex diagnostic challenge because no single gene variant determines risk; instead, risk is distributed across multiple loci, each contributing a small effect.
Key genetic variants linked to CKD include:
- APOL1: Predominantly found in individuals of African descent; linked to focal segmental glomerulosclerosis (FSGS) and HIV-associated nephropathy (HIVAN).
- PKD1 and PKD2: Mutations in these genes cause Polycystic Kidney Disease (PKD), leading to cyst growth and increased disease severity.
These factors not only predispose individuals to CKD but also dictate the speed of disease progression.
In recent years, genome-wide association studies (GWAS) have identified additional genetic loci associated with CKD, but these findings only represent a portion of the genetic risk. The polygenic architecture of CKD remains incompletely characterised, and the full genetic contribution to disease risk is not yet captured by existing loci or testing panels.
Precision medicine for CKD
Precision medicine is increasingly relevant to CKD management, particularly where genetic stratification can inform diagnosis, risk assessment, and treatment selection in ways that standard clinical criteria cannot. Broader adoption is constrained by gaps in testing infrastructure, limited provider awareness and interpretation support, and the added complexity of polygenic risk.
Genetic testing supports several dimensions of CKD care:
- Early diagnosis: In patients with PKD, genetic confirmation allows for earlier clinical planning and intervention before significant function is lost.
- Risk stratification: Individuals with APOL1 high-risk variants can be monitored more closely to reduce the likelihood of undetected progression to ESKD.
- Treatment selection: Patients with polycystic kidney disease may respond to treatments like tolvaptan, a vasopressin receptor antagonist shown to slow cyst growth.
- Transplant planning: Genetic data can inform donor-recipient matching and post-transplant management decisions.
Testing results can also have implications beyond the individual patient. When a pathogenic variant is identified, cascade screening can help identify at-risk relatives who may benefit from earlier evaluation and monitoring. This can also create opportunities to identify and engage broader populations of genetically characterized individuals eligible for future studies.
Genetic counseling is a core component of precision medicine workflows, helping patients and families understand results, disease trajectory implications, and impact on relatives. Integrating counseling into testing workflows ensures genetic information is actionable rather than simply informational.
Integrating genetic testing into routine CKD care
Current research has established key monogenic drivers of CKD and identified associated loci through GWAS, but the polygenic architecture of the disease — particularly its interaction with environmental and clinical variables — remains poorly resolved. Critical gaps remain, particularly in quantifying the combined effect of multiple low-risk variants, understanding gene-environment interactions, and validating polygenic risk scores across diverse populations.
These gaps have concrete implications for clinical development and trial design. Eligibility, stratification, and biomarker strategies may need to account for evolving variant interpretation and emerging genetic evidence. Building flexibility for updated testing panels and longitudinal data capture can reduce downstream protocol amendments and screen failures.
As the cost of sequencing continues to decline and clinical guidelines evolve to incorporate genetic risk data, integration of genetic testing into standard nephrology workflows is expected to expand.
In many cases, people are not diagnosed with genetic kidney disease until adulthood, often after significant progression. Earlier testing — whether through family-based screening or broader programs — can shift identification upstream, when monitoring and intervention options are more meaningful.
For individuals with identified high-risk variants such as APOL1, earlier clinical intervention has been associated with delayed progression to end-stage kidney disease. The breadth of population-level impact will depend on how widely validated genetic screening is adopted in nephrology practice.
Conclusion
Understanding the genetic basis of CKD supports earlier, more accurate diagnosis and reduces the risk of inappropriate treatment, delayed intervention, and preventable progression to end-stage disease. CKD spans monogenic etiologies with clearer inheritance patterns and polygenic forms in which risk is distributed across multiple loci, making stratification and interpretation more complex.
For clinical research programs, genetic insights shape trial design, patient identification, and stratification strategies. Integrating genetic testing, counseling, and patient engagement into a coordinated workflow is a defining factor in program success, particularly where eligibility depends on confirmed variants and where recontact may support future studies.
To explore how Sano Genetics supports genetic testing, patient qualification, and precision recruitment in CKD and related studies, get in touch.